AIPher Raises Hundreds of Millions of Yuan for AI Drug Discovery

The big picture: AIPher, an AI-native drug research and development company, has completed its Angel round of financing. The funds will primarily support the continued development of its DrugCLIP foundational drug model and PharmAgents AI drug R&D agent engine, establish a multi-modal wet-lab closed-loop system, and advance its proprietary and collaborative innovative drug pipelines. Its fastest-progressing pipeline has already entered the Pre-PCC (Pre-Preclinical Candidate) stage.

Why it matters:

• Redefining R&D: AIPher aims to transform drug discovery from a series of isolated prediction tasks into a continuous cycle of exploration, decision-making, validation, and learning, fundamentally reshaping how innovative drugs are developed.
• Addressing core challenges: Traditional drug development faces persistent challenges of long cycles, high costs, and low success rates. AIPher’s AI-native approach seeks to mitigate these by enhancing efficiency and success rates across the entire R&D process.
• Full-process integration: Moving beyond single-point AI tools, AIPher integrates foundational models like DrugCLIP for chemical space exploration and AI agents like PharmAgents for complex R&D decisions, aiming for a comprehensive, intelligent drug discovery system.

How it works:

• DrugCLIP foundation models: These models serve as the cornerstone for exploring vast chemical spaces, expanding AI’s coverage and enabling the discovery of truly novel candidate molecules, with related work published in ‘Science’.
• PharmAgents AI agents: This engine synthesizes multi-source scientific evidence and expert model outputs to make informed, complex R&D decisions within an enormous possibility space, driving real experimental validation.
• Continuous learning: The system is designed to continuously learn and evolve by converting experimental results, R&D processes, and expert feedback into learning signals, actively identifying the most promising next steps for validation.

The catch: The AI drug discovery sector is highly competitive, with numerous startups and established pharmaceutical giants vying for market share. While AI promises accelerated discovery, the transition from computational prediction to successful wet-lab validation and clinical trials remains a significant bottleneck, requiring substantial capital and facing high regulatory hurdles. AIPher’s success hinges on its ability to consistently translate AI-driven insights into viable, clinically impactful drug candidates faster and more cost-effectively than competitors.